Clinical Trial Update: Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease [EARLY_Phase 1]

View source ↗

Summary

An early-phase allogeneic anti-CD19 CAR-T therapy is being studied for refractory Graves' disease, and the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Disease

Drugs mentioned

• Allogeneic Anti-CD19 CAR-T

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Graves Disease | EARLY_Phase 1 | Status: RECRUITING